Medical Marijuana Inc (MJNA)

[Art Vandeley]

Salvation Life Sciences, Inc. – North American Joint Venture with Salvation
Botanicals BC Ltd.
On December 18, 2013, Kannalife™ entered into a Memorandum of Understanding (the
“Salvation MOU”) with Salvation Botanicals BC Ltd., a British Columbia corporation (“SBOT”)
and Salvation Biosciences, Inc., a Canadian corporation (“SBIO”). The Salvation MOU
describes the outline of terms for a proposed joint venture between SBOT and the Company.
Pursuant to the Salvation MOU, the Company will own 49% of the class A common stock and
49% of the class B preferred stock of Salvation Life Sciences, Inc., a newly formed Canadian
corporation (“SLSI”). The remaining 51% of SLSI will be owned by a combination of Canadian
national interests and SBOT. SBIO will be a party only in scientific research and development,
but will not own any shares in SLSI.
On April 11, 2014, SLSI was duly formed and incorporated as a federally registered company in
Canada.
SBOT is currently one of only a handful of selected producer licensees through Health Canada
under the new Marijuana for Medical Purposes Regulations (SOR 2013/119). Since 2001, Health
Canada has granted access to marihuana for medical purposes to Canadians who have had the
support of their physicians.
The business of SLSI will be centered on standardization and packaging of botanical
medicaments and patient wellness in Canada under the Marijuana for Medical Purposes
Regulations (SOR 2013/119). Under Division 5 – Packaging, Labeling, Shipping, subparagraph
64 of the Marijuana for Medical Purposes Regulations (SOR 2013/119), and the production and
sale of quality controlled and quality assured botanical medicaments derived from cannabis taxa
under the same regulations.
In addition to the intellectual property and business brought forth by the Company into the
potential joint venture with SLSI, SBOT is slated to bring the following products services and
competencies regarding medical application of cannabinoid based therapeutics:Page 25
Development of quality control and good manufacturing protocols
Identifying cannabinoid/terpene profiles for individual cannabis sativa/indica/ruderalis
strains
Determining the most effective extraction protocols as required for each unique finished
product
Applying specific cannabinoid profiles to specific conditions to maximize the efficacy of
the final product for each of those conditions
Testing sustained dosage levels through a process of observational study and clinical trial
Documenting results and publishing data
Intellectual Property in the form of GMP, SOPs, cannabinoid/terpene profiles, QA/QC
protocols
Consultation Services
Consumable Teas
Skin care based salves, creams, tinctures, infused oils and supplements
SBOT is also currently in the process of obtaining a narcotics Dealers License to analyze
medicinal cannabis. SBOT has passed its physical inspection and awaiting the approval of its
license. The license SBOT is applying for will enable SBOT to possess up to 5 KG’s of cannabis
for testing purposes, and preform extractions for analytical purposes. This type of license is the
prerequisite to acting in the capacity as a provider for the following:
Possess cannabis
Produce pharmacological/nutraceutical products for ourselves and others
Produce base materials and raw materials for production
Sale of pharmacological/nutraceutical cannabis products
Package material/ products
Transport and delivery
Perform laboratory analysis
Perform research and development
Conduct clinical trialsPage 26
Perform virtually any activity required to conduct business under the controlled drugs and
substances act